Shares of Fonar Corporation (NASDAQ:FONR) rose by 15.67% in the past week and 50.63% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 12.02% and the outperformance increases to 46.6% for the last 4 weeks.
Fonar Corporation (NASDAQ:FONR) traded negative at $13.44. On an intraday basis, the price dropped -0.09 points or -0.67%. The composite uptick value was $0.16 million while the combined downtick value was $0.02.
Fonar Corporation (NASDAQ:FONR) has lost 1.72% during the past week and dropped 8.83% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.85%.
While zero growth is indeed an issue for the company - and it might be one of the reasons why it trades at a low multiple - the possibility of another acquisition, coupled with a balance sheet that has ability to do just that, is not.
Fonar Corporation is engaged in the design, manufacture, sale, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, injuries, and other medical conditions.
It was made public in an electronic document filed with the U.S. Security & Exchange Commission that Raymond Damadian, who works for Fonar Corporation (NASDAQ:FONR) 15.65 +0.53 3.51% , and is currently the President made an insider transaction on ...
Fonar Corporation (NASDAQ:FONR) is engaged in the research, development, productions, and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (MRI) for the detection of and diagnosis of human diseases.